Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

204.56
+2.901.44%
Post-market: 204.560.00000.00%16:10 EDT
Volume:140.34K
Turnover:28.87M
Market Cap:4.08B
PE:33.37
High:208.89
Open:203.17
Low:201.28
Close:201.66
52wk High:227.92
52wk Low:93.58
Shares:19.94M
Float Shares:19.46M
Volume Ratio:0.54
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.13
EPS(LYR):6.13
ROE:13.47%
ROA:2.36%
PB:4.01
PE(LYR):33.37

Loading ...

Ligand files automatic mixed securities shelf

TIPRANKS
·
Feb 28

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Total Revenue Range $245M-$285M, vs. FactSet Est of $265.7M

MT Newswires Live
·
Feb 26

Ligand’s FY 2025 royalty revenue rises 48% to USD 161.0 million

Reuters
·
Feb 26

Ligand Pharmaceuticals Q4 Adj. EPS $2.02 Beats $1.56 Estimate, Sales $59.666M Beat $55.589M Estimate.

Benzinga
·
Feb 26

BRIEF-Ligand Pharmaceuticals Q4 EPS USD 2.12

Reuters
·
Feb 26

Ligand Pharmaceuticals Q4 Pretax Profit USD 56.78 Million

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals: Reiterates FY Guidance of $245-$285 Mln in Revenues & Adj EPS of $8.00-$9.00

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals: Expects 2026 Royalty Revenue to Be in Range of $200 Million to $225 Million

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals Q4 Basic EPS USD 2.27

THOMSON REUTERS
·
Feb 26

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 25

Ligand price target raised to $239 from $231 at H.C. Wainwright

TIPRANKS
·
Feb 25

Earning Preview: Ligand Pharmaceuticals this quarter’s revenue is expected to increase by 42.45%, and institutional views are limited

Earnings Agent
·
Feb 19

Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Feb 16

Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Share Price Weakness And Strong 1 Year Return

Simply Wall St.
·
Feb 15

Has Ligand Pharmaceuticals (LGND) Run Too Far After Its 59% One-Year Share Price Surge?

Simply Wall St.
·
Feb 13

MedCap AB erzielt im Gesamtjahr 2025 einen Umsatz von 2.108 Mio. SEK und eine EBITA-Marge von 18 Prozent

Reuters
·
Feb 06

Ligand Pharmaceuticals Director John W. Kozarich Reports Disposal of Common Shares

Reuters
·
Feb 05

Ligand Pharmaceuticals (LGND) Valuation Check As Partner Milestones Expand Royalty And Growth Potential

Simply Wall St.
·
Feb 05